PT  - JOURNAL ARTICLE
AU  - Singh, S. S.
AU  - Mohapatra, D. K.
TI  - Predictive Analysis for COVID-19 Spread in India by Adaptive Compartmental Model
AID  - 10.1101/2020.07.08.20148619
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.08.20148619
4099  - http://medrxiv.org/content/early/2020/07/09/2020.07.08.20148619.short
4100  - http://medrxiv.org/content/early/2020/07/09/2020.07.08.20148619.full
AB  - The role of mathematical modelling in predicting spread of an epidemic is of vital importance. The purpose of present study is to develop and apply a computational tool for predicting evolution of different epidemiological variables for COVID-19 in India. We propose a dynamic SIRD (Susceptible-Infected-Recovered-Dead) and SEIRD (Susceptible-Exposed-Infected-Recovered-Dead) model for this purpose. In the dynamic model, time dependent infection rate is assumed for estimating evolution of different variables of the model. Parameter estimation of the model is the first step of the analysis which is performed by least square optimization of priori data. In the second step of the analysis, simulation is carried out by using evaluated parameters for prediction of the outbreak. The computational model has been validated against real data for COVID-19 outbreak in Italy. Time to reach peak, peak infected cases and total reported cases were compared with actual data and found to be in very good agreement. Next the model is applied for the case of India and various Indian states to predict different epidemiological parameters. Priori data was taken from the beginning of nation-wide lockdown on 24 March to 6 July. It was found that peak of the outbreak may reach in the month of August-September with maximum 4-5 lakhs active cases at peak. Total number of reported cases all over India would be in between three to five millions. State wise, Maharashtra, Tamilnadu and Delhi would be worst affected.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding were taken for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Relvent ethical guidelines have been followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are taken from public domain on COVID-19. http://www.covid19india.org